Overview

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Status:
Not yet recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether Mycobacterium bovis rBCGΔureC::hly (VPM1002) vaccination and Mycobacterium bovis bacille Calmette-Guérin (BCG) revaccination are safe and immunogenic in pre-adolescents with and without HIV and with and without Mycobacterium tuberculosis (M.tb) sensitization.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Collaborators:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)

Treatments:

BCG Vaccine
Vaccines